Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

July 18, 2021

Study Completion Date

July 18, 2021

Conditions
COVID-19Lung Infection
Interventions
DRUG

Opaganib

Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).

DRUG

Placebo

Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).

Trial Locations (57)

00000

ABC-201 Site 901, Detroit

Unknown

ABC-201 Site 408, Belo Horizonte

ABC-201 Site 411, Belo Horizonte

ABC-201 Site 405, Joinville

ABC-201 Site 404, Paraná

ABC-201 Site 410, Passo Fundo

ABC-201 Site 409, Porto Alegre

ABC-201 Site 402, São Bernardo do Campo

ABC-201 Site 401, São Paulo

ABC-201 Site 403, São Paulo

ABC-201 Site 407, Tubarão

ABC-201 Site 604, Medellín

ABC-201 Site 603, Bogotá

ABC-201 Site 605, Cundinamarca

ABC-201 Site 602, Medellín

ABC-201 Site 601, Santiago de Cali

ABC-201 Site 708, Ashkelon

ABC-201 Site 702, Ashdod

ABC-201 Site 704, Holon

ABC-201 Site 701, Jerusalem

ABC-201,Site 709, Kfar Saba

ABC-201 Site 705, Nahariya

ABC-201 Site 706, Nazareth

ABC-201 Site 703, Safed

ABC-201 Site 203, Alessandria

ABC-201 Site 201, Lecco

ABC-201 Site 202, Milan

ABC-201 Site 204, Torino

ABC-201 Site 501, Mexico City

ABC-201 Site 503, Sinaloa

ABC-201 Site 655, Lima

ABC-201 Site 303, Bolesławiec

ABC-201 Site 306, Katowice

ABC-201 Site 304, Koszalin

ABC-201 Site 308, Lodz

ABC-201 Site 307, Lublin

ABC-201 Site 302, Ostróda

ABC-201 Site 301, Racibórz

ABC-201 Site 305, Wroclaw

ABC-201 Site 110, Barnaul

ABC-201 Site 122, Kirovsk

ABC-201 Site 101, Moscow

ABC-201 Site 132, Moscow

ABC-201 Site 120, Murmansk

ABC-201 Site 103, Ryazan

ABC-201 Site 114, Ryazan

ABC-201 Site 109, Saint Petersburg

ABC-201 Site 111, Saint Petersburg

ABC-201 Site 129, Saint Petersburg

ABC-201 Site 108, Saratov

ABC-201 Site 102, Smolensk

ABC-201 Site 104, Tver'

ABC-201 Site 118, Volgograd

ABC-201 Site 112, Yaroslavl

ABC-201 Site 253, Antrim

ABC-201 Site 251, Gillingham

ABC-201 Site 252, Taunton

All Listed Sponsors
lead

RedHill Biopharma Limited

INDUSTRY

NCT04467840 - Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter